The Food and Drug Administration will get a 1% funding increase from President Barack Obama's proposed fiscal 2015 budget, a level some say is not enough to cover the agency's new responsibilities and the increasingly global nature of the products it regulates.
The Food and Drug Administration will get a 1% funding increase from President Barack Obama's proposed fiscal 2015 budget, a level some say is not enough to cover the agency's new responsibilities and the increasingly global nature of the products it regulates. The budget requests roughly $2.6 billion for the FDA in fiscal 2015, which begins in October. Included is $25 million more to oversee controversial high-risk compounding pharmacies.
“Given that the FDA regulates about 25 cents of every dollar of the gross domestic product, it does not have enough money to fulfill its public health mission,” said Kasey Thompson, vice president of policy, planning and communications for the American Society of Health-System Pharmacists. He is also president and chairman of the Alliance for a Stronger FDA.
Read the full story here: http://bit.ly/1fJjNhc
Source: Modern Healthcare
How Can Digital Care Programs Aid Those With Chronic Musculoskeletal Pain?
June 9th 2020On this episode of Managed Care Cast, we speak with Jeffrey Krauss, MD, chief medical officer of Hinge Health and Stanford Clinical assistant professor, about the efficacy of a 12-week digital care program aimed to reduce lower back and knee pain in a real-world population.
Listen
Understanding the Impact of Inappropriate Opioid Prescribing Practices
April 19th 2019Deaths from drug overdoses have become the leading cause of death for Americans under age 50, which can largely be attributed to prescription opioids. Due to the role of prescription opioids, understanding prescribing patterns and identifying inappropriate prescribing are crucial for changing the course of the epidemic.
Listen
MBSR Reduced Pain Perception in Patients With Migraine
December 19th 2020The finding about mindfulness-based stress reduction (MBSR) was a secondary outcome of the double-blinded, randomized, placebo-controlled clinical trial. The primary outcome—a reduction in the frequency of migraines—was not reached.
Read More